

AMBIT BIOSCIENCES CORP  
Form 8-K  
September 04, 2014

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**  
**of the Securities Exchange Act of 1934**

**August 31, 2014**

Date of Report (Date of earliest event reported)

**Ambit Biosciences Corporation**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction  
of incorporation)

**001-35919**  
(Commission File Number)

**33-0909648**  
(IRS Employer Identification No.)

**11080 Roselle St.**

**92121**

Edgar Filing: AMBIT BIOSCIENCES CORP - Form 8-K

**San Diego, California**  
(Address of principal executive offices)

(Zip Code)

Registrant's telephone number, including area code: **(858) 334-2100**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 5.03**

**Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.**

On August 31, 2014, the Board of Directors of Ambit Biosciences Corporation (the *Company*) adopted an amendment (the *Amendment*) to the *Company's* Amended and Restated Bylaws (the *Bylaws*), effective immediately, to add a new Article XV, Section 47 to the Bylaws. The new provision provides that, unless the *Company* consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware shall be the sole and exclusive forum for (i) any derivative action or proceeding brought on behalf of the *Company*, (ii) any action asserting a claim of breach of a fiduciary duty owed by any director, officer or other employee of the *Company* to the *Company* or the *Company's* stockholders, (iii) any action asserting a claim against the *Company* arising pursuant to any provision of the Delaware General Corporation Law, the certificate of incorporation or the bylaws of the *Company*, or (iv) any action asserting a claim governed by the internal affairs doctrine. The provision further provides that any person or entity purchasing or otherwise acquiring any interest in shares of capital stock of the *Company* shall be deemed to have notice of and consented to the provision.

The foregoing summary of the Amendment is qualified in its entirety by reference to the complete text of the Amendment, a copy of which is attached to this Current Report on Form 8-K as Exhibit 3.1 and incorporated herein by reference.

**Item 9.01**

**Financial Statements and Exhibits.**

(d) Exhibits

<b>Exhibit No.</b>	<b>Description</b>
3.1	Amendment to Amended and Restated Bylaws of Ambit Biosciences Corporation.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Ambit Biosciences Corporation**

Dated: September 4, 2014

By: */s/ Alan Fuhrman*  
Alan Fuhrman  
Chief Financial Officer

**INDEX TO EXHIBITS**

<b>Exhibit No.</b>	<b>Description</b>
3.1	Amendment to Amended and Restated Bylaws of Ambit Biosciences Corporation.